Prospectus regarding Biovitrum's preferential rights issue is now available
The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore. Board of Biovitrum AB (publ) has prepared the prospectus for the purpose of the preferential rights issue. This prospectus has been approved and registered at the Swedish Financial Supervisory Authority and is now available on Biovitrum's website www.biovitrum.com, Carnegie Investment Bank AB's website www.carnegie.se, ABG Sundal Collier AB's website www.abgsc.com, Handelsbanken Capital Markets' website www.handelsbanken.se/aktuellaerbjudanden, and the Swedish Financial Supervisory Authority's website www.fi.se. The prospectus will be distributed to Biovitrum's shareholders registered by name and can also be ordered from Carnegie Investment Bank AB during business hours by telephoning +46 8-588 694 83. For further information, please contact: Martin Nicklasson, CEO Biovitrum Phone: +46 8 697 20 00 Göran Arvidson, CFO Biovitrum Phone: +46 70 633 30 42 Erik Kinnman, VP Investor Relations Biovitrum Phone: +46 73 422 15 40 erik.kinnman@biovitrum.com About Biovitrum Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the Transaction). Biovitrum's head office is located in Sweden and the share is listed on the NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com. IMPORTANT NOTICE: The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore. The information in this press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act"). The securities mentioned herein may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States. The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions. The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 11 a.m. CET on December 9th, 2009.